Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

NeoGenomics, Inc. - Common Stock (NQ: NEO )

14.42 +0.51 (+3.67%)
Streaming Delayed Price Updated: 4:00 PM EST, Feb 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about NeoGenomics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
NeoGenomics to Report Second Quarter 2023 Financial Results on August 8, 2023
Via ACCESSWIRE
NeoGenomics Expands Board of Directors with Appointments of Three Independent Directors
Via ACCESSWIRE
Guardant Health Stock Reaches 80-Plus Relative Strength Rating Benchmark
On Friday, Guardant Health stock hit a key performance benchmark, with its Relative Strength Rating rising to 82, up from 78 the day before. 
Via Investor's Business Daily
NeoGenomics' RaDaR Assay for Minimal Residual Disease Receives First Commercial Coverage
Via ACCESSWIRE
NeoGenomics and German Breast Group Announce New Data Demonstrating Clinical Potential of the RaDaR MRD Assay in HR+/HER2- Breast Cancer
Via ACCESSWIRE
NeoGenomics to Participate at the Goldman Sachs 44th Annual Global Healthcare Conference
Via ACCESSWIRE
NeoGenomics's Return On Capital Employed Insights
Via Benzinga
NeoGenomics: Q1 Earnings Insights
Via Benzinga
NeoGenomics Reports Q1 Topline Growth, Lifts Annual Guidance, Shares Soar
NeoGenomics Inc (NASDAQ: NEO) reported Q1 revenues of $137.22 mill 
Via Benzinga
NeoGenomics to Showcase the Transformational Impact of RaDaR(R) Assay for Molecular Residual Disease and Recurrence Monitoring at ASCO
Via ACCESSWIRE
Benzinga's Top Ratings Upgrades, Downgrades For May 16, 2023
Via Benzinga
Earnings Scheduled For May 12, 2023
Companies Reporting Before The Bell • Honda Motor Co (NYSE:HMC) is expected to report earnings for its fourth quarter. 
Via Benzinga
Analyst Expectations for NeoGenomics's Future
Via Benzinga
NeoGenomics Reports First Quarter 2023 Results
Via ACCESSWIRE
What 9 Analyst Ratings Have To Say About NeoGenomics
Via Benzinga
Looking Into NeoGenomics's Return On Capital Employed
Via Benzinga
Why PRA Group Shares Are Trading Lower By 44%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers TScan Therapeutics, Inc. (NASDAQ: TCRX) shares gained 118% to $4.68 after the company and Amgen announced collaboration to identify novel targets in Crohn's disease. 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 9, 2023
Via Benzinga
Analyst Ratings for NeoGenomics
Via Benzinga
McKesson, ICU Medical, Novavax And Other Big Stocks Moving Higher On Tuesday
U.S. stocks traded lower, with the Dow Jones dropping around 50 points on Tuesday. Here are some big stocks recording gains in today’s session. 
Via Benzinga
NeoGenomics to Participate at the BofA Securities 2023 Healthcare Conference
Via ACCESSWIRE
NeoGenomics, Inc. (NASDAQ:NEO) Long Term Investor Alert: Investigation of Potential Wrongdoing
San Diego, CA -- (SBWIRE) -- 04/20/2023 -- An investigation concerning potential breaches of fiduciary duties by certain directors and officers of NeoGenomics, Inc was announced. 
Via SBWire
NeoGenomics to Announce First Quarter 2023 Financial Results
Via ACCESSWIRE
NeoGenomics to Participate at the 22nd Annual Needham Virtual Healthcare Conference
Via ACCESSWIRE
NeoGenomics to Share Nine Abstracts at the American Association of Cancer Research (AACR) Annual Meeting 2023
Via ACCESSWIRE
NeoGenomics to Host Investor Day on April 4, 2023
Via ACCESSWIRE
Massive Bio and NeoGenomics Announce Collaboration to Accelerate Oncology Drug Discovery and Improve Patient Care
From Massive Bio, Inc.
Via Business Wire
3 Supercharged Stocks Near 52-Week Highs That Could Keep Climbing
The high-flyers have soared to new heights and further gains could be up ahead. 
Via The Motley Fool
NeoGenomics Announces Commercial Availability of the RaDaR(R) Molecular Residual Disease Test
Via ACCESSWIRE
NeoGenomics Expands NGS Portfolio with Launch of Neo Comprehensive(TM) - Solid Tumor CGP and Neo Comprehensive(TM) - Myeloid Disorders CGP
Via ACCESSWIRE
< Previous 1 2 3 4 5 6 7 8 9
...
11 12 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.